Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743003 | 1.00 | TRPV1 (0.46) | TRPV1PRKCQPRKCDKITAVPR1A | |
| SCHEMBL232057 | 0.84 | TRPV1 (0.47) | TRPV1PRKCQPRKCDKITHSD11B1 | |
| SCHEMBL2419489 | 0.84 | PRKCQ (0.45) | PRKCQPRKCDKITMAPK13MAPK12 | |
| SCHEMBL232058 | 0.84 | TRPV1 (0.47) | TRPV1PRKCQPRKCDKITHSD11B1 | |
| SCHEMBL2421374 | 0.84 | PRKCQ (0.45) | PRKCQPRKCDKITMAPK13MAPK12 | |
| SCHEMBL2425193 | 0.84 | PRKCQ (0.45) | PRKCQPRKCDKITMAPK13MAPK12 | |
| SCHEMBL3707817 | 0.84 | TRPV1 (0.47) | TRPV1PRKCQPRKCDKITHSD11B1 | |
| SCHEMBL8651595 | 0.81 | PDE10A (0.45) | PRKCQPRKCDKIT | |
| SCHEMBL2899849 | 0.80 | KDM4E (0.50) | PRKCQPRKCDHSD11B1 | |
| SCHEMBL1734757 | 0.80 | EPHX2 (0.66) | TRPV1HSD11B1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | TRPV1 1/4885PRKCQ 2109/4885PRKCD 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.